Candel Therapeutics: Potentially The Next Exciting Oncology Story

Company Overview - Candel Therapeutics is a pre-clinical stage company focused on researching two drugs: CAN-2409 and CAN-3110, with CAN-2409 being the most advanced candidate [1]. Drug Development - CAN-2409 is currently the most developed drug in Candel Therapeutics' pipeline, while CAN-3110 is in an earlier stage and may have long-term potential but is not yet significant compared to CAN-2409 [1].